Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma - Top-Institutions - MDSpire

Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma

  • By

  • Karan L. Chohan

  • Rina L. Welkie

  • James Godfrey

  • Steven Bair

  • Lorenzo Falchi

  • Manali Kamdar

  • Ajay Major

  • Wendy Dixon

  • Jennifer Crombie

  • Reid Merryman

  • Sonia Godbole

  • Gilles Salles

  • Omnia Farahat

  • Amy Ayers

  • Ayushi Chauhan

  • Alex Herrera

  • Geoffrey Shouse

  • Sairah Ahmed

  • Yazeed Sawalha

  • May 22, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Collaborative US Bispecific Consortium
    Collaborative US Bispecific Consortium

    N/A, N/A

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Shenzhen University General Hospital
    Shenzhen University General Hospital

    Shenzhen, Guangdong

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma

  • by Karan L. Chohan, Rina L. Welkie, James Godfrey, Steven Bair, Lorenzo Falchi, Manali Kamdar, Ajay Major, Wendy Dixon, Jennifer Crombie, Reid Merryman, Sonia Godbole, Gilles Salles, Omnia Farahat, Amy Ayers, Ayushi Chauhan, Alex Herrera, Geoffrey Shouse, Sairah Ahmed, Yazeed Sawalha

  • May 22, 2026

Related Content

Biotech exec Jeremy Levin on the industry’s strategic turning point

FOXA2 in cancer: from fundamental biology to clinical translation

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report